Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial

Mingwei Wei(Jiangsu Provincial Center for Disease Control and Prevention), Yongjiang Liu(Collaborative Innovation Center of Advanced Microstructures), Jingxin Li(Jiangsu Provincial Center for Disease Control and Prevention), Weiwei Han(Nanjing Medical University), Jing Zhang(Children's Hospital of Fudan University), Huilong Yu(Beijing Red Cross Blood Center)
Vaccines
May 13, 2025
Cited by 2


Related Papers